1002 related articles for article (PubMed ID: 19450752)
41. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
42. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
[TBL] [Abstract][Full Text] [Related]
44. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
45. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
[TBL] [Abstract][Full Text] [Related]
46. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
47. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.
Ivanov V; Faucher C; Mohty M; Bilger K; Ladaique P; Sainty D; Arnoulet C; Chabannon C; Vey N; Camerlo J; Bouabdallah R; Maraninchi D; Bardou VJ; Blaise D
Transfusion; 2004 Apr; 44(4):501-8. PubMed ID: 15043564
[TBL] [Abstract][Full Text] [Related]
48. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
49. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
50. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
51. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.
Inamoto Y; Nishida T; Suzuki R; Miyamura K; Sao H; Iida H; Naoe T; Maruyama F; Hirabayashi N; Hamaguchi M; Iseki T; Kami M; Yano K; Takeyama H; Morishita Y; Morishima Y; Kodera Y
Bone Marrow Transplant; 2007 Jan; 39(1):25-30. PubMed ID: 17115063
[TBL] [Abstract][Full Text] [Related]
52. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
53. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin.
Nakai K; Kanda Y; Mineishi S; Saito T; Ohnishi M; Niiya H; Chizuka A; Takeuchi T; Matsubara H; Kami M; Makimoto A; Tanosaki R; Kunitoh H; Tobinai K; Takaue Y
Bone Marrow Transplant; 2002 Feb; 29(3):237-41. PubMed ID: 11859396
[TBL] [Abstract][Full Text] [Related]
54. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
55. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
56. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
Ruiz-Argüelles GJ; Rangel JD; Ponce-de-León S; González-Déctor L; Reyes-Núñez V; Garcés-Eisele J
Am J Hematol; 2004 Apr; 75(4):200-4. PubMed ID: 15054809
[TBL] [Abstract][Full Text] [Related]
57. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Narreddy S; Mellon-Reppen S; Abidi MH; Klein JL; Peres E; Heilbrun LK; Smith D; Alangaden G; Chandrasekar PH
Transpl Infect Dis; 2007 Mar; 9(1):3-10. PubMed ID: 17313464
[TBL] [Abstract][Full Text] [Related]
58. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
59. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
[TBL] [Abstract][Full Text] [Related]
60. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
